Nitrosoureas: Clinical and Experimental Considerations in the Treatment of Brain Tumors
The nitrosoureas have been in clinical usage in the treatment of primary and secondary brain tumors since 1969. Either as a tribute to the activity of these drugs or as an example of our ineptness in discovering other active drugs, the nitrosoureas, particularly BCNU, remain our most active agents.
KeywordsBrain Tumor Malignant Glioma Brain Tumor Model Secondary Brain Tumor Brain Tumor Therapy
Unable to display preview. Download preview PDF.
- 4.Levin VA and Wilson CB: Pharmacological considerations in brain tumor chemotherapy. IN: Brain Turno Chemotherapy, D Fewer, CB Wilson, VA Levin (eds) Charles C Thomas, Springfield, Chapter 3 (in press).Google Scholar
- 8.Levin VA, Crafts D, Wilson CB, Boldrey EB, Enot KJ, Pischer T, and Seager M: A phase II study of BCNU-Procarbazine in recurrent malignant gliomas (in preparation).Google Scholar
- 9.Crafts D, Wilson CB, Levin VA, Boldrey EB, Pischer T, and Enot KJ: Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU and vincristine (submitted).Google Scholar
- 13.Levin VA and Kabra PM: Brain and tumor pharmacokinetics of BCNU and CCNU following i.v. and intracarotid artery (i.e.a.) administration. Proc Amer Assoc Cancer Res 16:19, 1975.Google Scholar